Shares of Suven Life Sciences surged over 7 per cent in Tuesday's trade as the company has received a patent from New Zealand for a drug used for the treatment of neuro-degenerative diseases.
The stock opened at Rs 181.85, touched an intraday high of Rs 198.80 and a low of Rs 179.85. The company shares ended higher by 5.5 per cent at Rs 190.95 on the BSE. On the NSE, the stock closed up by 5.86 per cent at Rs 191.50.
In a BSE filing today, Suven Life said it has been granted “one product patent from New Zealand corresponding to the New Chemical Entities (NCEs) for the treatment of disorders associated with neuro-degenerative diseases''.
The patents are valid till 2034, the company added.
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.